** Shares of drug developer Hoth Therapeutics HOTH.O jump 96.4% to $1.61 premarket
** Co announces positive interim safety and efficacy results from a mid-stage trial testing its experimental treatment to treat skin toxicity caused due to side effects of cancer treatments
** Co was testing the treatment, HT-001, to address skin toxicities linked to a type of cancer medication called EGFR inhibitors
** Data from the study shows that 100% of patients enrolled in the trial had significant skin toxicity improvement by six weeks
** 66% of patients reported reduced pain and itching scores - HOTH
** Co says no treatment-related adverse effects have been reported
** Up to last close, stock had fallen ~47% in the past 12 months
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。